Overview
Biotechnology firm reported Q4 EPS and net income beat analyst expectations
Company entered strategic financing agreement with Sixth Street for up to $500 mln
Company expanded liver-targeted genetic disease franchise with BEAM-304 for PKU
Outlook
Beam expects to file IND for BEAM-304 in 2026
Beam plans BLA submission for risto-cel by year-end 2026
Beam anticipates updated BEAM-302 data by Q1 2026
Result Drivers
BEAM-304 EXPANSION - Beam expanded its liver-targeted genetic disease franchise with BEAM-304 for PKU, leveraging base editing technology to address mutations in the PAH gene
STRATEGIC FINANCING - Beam secured a strategic financing agreement with Sixth Street for up to $500 mln to support the launch of risto-cel in SCD
Company press release: ID:nGNX2YX5lq
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 License and Collaboration Revenue | $114.11 mln | ||
Q4 EPS | Beat | $2.33 | -$0.99 (15 Analysts) |
Q4 Net Income | Beat | $244.30 mln | -$91.17 mln (15 Analysts) |
Q4 Operating Income | Beat | -$17.45 mln | -$117.30 mln (14 Analysts) |
Q4 Pretax Profit | Beat | $244.30 mln | -$95.99 mln (13 Analysts) |
Q4 Operating Expenses | $131.55 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Beam Therapeutics Inc is $45.00, about 58.8% above its February 23 closing price of $28.33
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)